The Effect of Recombinant Erythropoietin on the Levels of Hemoglobin, Mean Corpuscular Volume, LDH, and Length of Stay at the Hospital in COVID-19 Patients
| Author | HamidReza Samimagham | en |
| Author | Mehdi Hassaniazad | en |
| Author | Dariush Hooshyar | en |
| Author | Maryam Haddad | en |
| Author | Mohsen Arabi | en |
| Author | Mitra Kazemi Jahromi | en |
| Orcid | HamidReza Samimagham [0000-0002-6636-198X] | en |
| Orcid | Dariush Hooshyar [0000-0002-0283-5680] | en |
| Orcid | Mitra Kazemi Jahromi [0000-0002-9127-3594] | en |
| Issued Date | 2022-06-30 | en |
| Abstract | Background: Erythropoietin plays a significant role in the growth of red blood cells, hemoglobin levels, and tissue oxygenation in critically ill patients, as well as anti-inflammatory and neuroprotective effects. Objectives: This study aimed to evaluate the effect of recombinant erythropoietin on improving COVID-19 patients. Methods: This study was conducted on 20 COVID-19 participants with hemoglobin of ≥ 9. The inclusion criteria was at least one severe COVID-19 symptom/sign in this interventional study. The primary outcome was a combination of hospital stay length and paraclinical evaluation (LDH and hemoglobin level). The outcomes and side effects were evaluated on day 0 (before the intervention) and five (post-intervention). Results: The mean hemoglobin level was 10 ± 1.1 gr/dL in the intervention group and 8 ± 0.7 gr/dL in the control group post-treatment, indicating a significant difference between the groups (P = 0.04). The mean hospital stay length (6 ± 2 days) in the intervention group was significantly less than the control group (9 ± 4 days) (P = 0.001). At the end of the treatment, the mean LDH was significantly lower in the intervention group (503 ± 264 µ/L) than in the control group (725 ± 320 µ/L; P = 0.017). Conclusions: According to the results, this study provides the first solid evidence for the positive effects of recombinant erythropoietin on COVID-19. | en |
| DOI | https://doi.org/10.5812/jkums-126623 | en |
| Keyword | Recombinant Erythropoietin | en |
| Keyword | COVID-19 | en |
| Keyword | Coronavirus 2 Disease, and Immunity | en |
| Publisher | Brieflands | en |
| Title | The Effect of Recombinant Erythropoietin on the Levels of Hemoglobin, Mean Corpuscular Volume, LDH, and Length of Stay at the Hospital in COVID-19 Patients | en |
| Type | Research Article | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- jkums-26-2-126623.pdf
- Size:
- 162.68 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF